🎉 M&A multiples are live!
Check it out!

Coherus BioSciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Coherus BioSciences and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Coherus BioSciences Overview

About Coherus BioSciences

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.


Founded

2010

HQ

United States of America
Employees

228

Website

coherus.com

Financials

LTM Revenue $219M

LTM EBITDA -$117M

EV

$257M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Coherus BioSciences Financials

Coherus BioSciences has a last 12-month revenue of $219M and a last 12-month EBITDA of -$117M.

In the most recent fiscal year, Coherus BioSciences achieved revenue of $267M and an EBITDA of $60.9M.

Coherus BioSciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Coherus BioSciences valuation multiples based on analyst estimates

Coherus BioSciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $257M $267M XXX XXX XXX
Gross Profit $141M $98.3M XXX XXX XXX
Gross Margin 55% 37% XXX XXX XXX
EBITDA -$194M $60.9M XXX XXX XXX
EBITDA Margin -75% 23% XXX XXX XXX
Net Profit -$292M -$238M XXX XXX XXX
Net Margin -113% -89% XXX XXX XXX
Net Debt $408M $370M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Coherus BioSciences Stock Performance

As of April 15, 2025, Coherus BioSciences's stock price is $1.

Coherus BioSciences has current market cap of $113M, and EV of $257M.

See Coherus BioSciences trading valuation data

Coherus BioSciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$257M $113M XXX XXX XXX XXX $0.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Coherus BioSciences Valuation Multiples

As of April 15, 2025, Coherus BioSciences has market cap of $113M and EV of $257M.

Coherus BioSciences's trades at 1.2x LTM EV/Revenue multiple, and -2.2x LTM EBITDA.

Analysts estimate Coherus BioSciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Coherus BioSciences and 10K+ public comps

Coherus BioSciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $257M XXX XXX XXX
EV/Revenue 1.0x XXX XXX XXX
EV/EBITDA 4.2x XXX XXX XXX
P/E 4.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -12.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Coherus BioSciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Coherus BioSciences Valuation Multiples

Coherus BioSciences's NTM/LTM revenue growth is -52%

Coherus BioSciences's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Coherus BioSciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Coherus BioSciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Coherus BioSciences and other 10K+ public comps

Coherus BioSciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 4% XXX XXX XXX XXX
EBITDA Margin 23% XXX XXX XXX XXX
EBITDA Growth -131% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -30% XXX XXX XXX XXX
Revenue per Employee $1.2M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 35% XXX XXX XXX XXX
Opex to Revenue 98% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Coherus BioSciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Coherus BioSciences M&A and Investment Activity

Coherus BioSciences acquired  XXX companies to date.

Last acquisition by Coherus BioSciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Coherus BioSciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Coherus BioSciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Coherus BioSciences

When was Coherus BioSciences founded? Coherus BioSciences was founded in 2010.
Where is Coherus BioSciences headquartered? Coherus BioSciences is headquartered in United States of America.
How many employees does Coherus BioSciences have? As of today, Coherus BioSciences has 228 employees.
Who is the CEO of Coherus BioSciences? Coherus BioSciences's CEO is Mr. Dennis M. Lanfear.
Is Coherus BioSciences publicy listed? Yes, Coherus BioSciences is a public company listed on NAS.
What is the stock symbol of Coherus BioSciences? Coherus BioSciences trades under CHRS ticker.
When did Coherus BioSciences go public? Coherus BioSciences went public in 2014.
Who are competitors of Coherus BioSciences? Similar companies to Coherus BioSciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Coherus BioSciences? Coherus BioSciences's current market cap is $113M
What is the current revenue of Coherus BioSciences? Coherus BioSciences's last 12-month revenue is $219M.
What is the current EBITDA of Coherus BioSciences? Coherus BioSciences's last 12-month EBITDA is -$117M.
What is the current EV/Revenue multiple of Coherus BioSciences? Current revenue multiple of Coherus BioSciences is 1.2x.
What is the current EV/EBITDA multiple of Coherus BioSciences? Current EBITDA multiple of Coherus BioSciences is -2.2x.
What is the current revenue growth of Coherus BioSciences? Coherus BioSciences revenue growth between 2023 and 2024 was 4%.
Is Coherus BioSciences profitable? Yes, Coherus BioSciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.